The efficacy and safety of IL-13 inhibitors in atopic dermatitis: A systematic review and meta-analysis.

ABSTRACT:

Background

Several clinical trials have evaluated the efficacy and safety of interleukin-13 (IL-13) with lebrikizumab and tralokinumab in patients with moderate to severe atopic dermatitis (AD). However, the safety and efficacy of IL-13 inhibitors as a potent biologic for AD remain elusive.

Objective

To assess the efficacy and safety of IL-13 inhibitors in moderate to severe AD.

Method

Randomized clinical trials (RCTs), comparing IL-13 inhibitors vs placebo treatment in patients with moderate to severe AD, were identified from public database from its inception to November 9^th, 2021. The study was registered in PROSPERO (CRD42021254920).

Results

Six studies reporting 7 RCTs involving 2946 patients with moderate-to-severe AD were included for the pool

SUBMITTER: Zhang Y 

PROVIDER: S-EPMC9364267 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature